

Report 2021, CampusPharma AB, Norge

Published: 2022

	Full name <i>(article 2)</i>	HCPs: City of Principal Practice HCOs: city of practice (registered address) <i>(article 9)</i>	Country of principal practice <i>(article 1)</i>	Principal practice address (e.g. clinic/ office/ healthcare unit/department) <i>(article 9)</i>	Unique identifier - OPTIONAL <i>(article 9)</i>	Donations to HCOs (article 9)	Contribution to costs of events (article 9)			Fee for service and consultancy (article 9)		TOTAL OPTIONAL	
							Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an event	Registration fees	Travel and accommodation	Fees (Euro)	Related expenses agreed in the fee for service or consultancy contract, including travel and accommodation		
HCPs	<i>INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate).</i>												
	Inger Øverlie	Oslo	Norge	Vennersborgveien 28 0281 Oslo		N/A	N/A	N/A	N/A	8 000 NOK	0	8 000 NOK	
	<i>OTHER, not included above - where information cannot be disclosed on an individual basis with regard to GDPR.</i>												
	Aggregate amount attributable to transfers of value to such Recipients - article 10						N/A	N/A	N/A	N/A	Aggregate	Aggregate	
	Number of Recipients						N/A	N/A	N/A	N/A	Amount	Amount	
	% of total number of recipients of individual HCPs						N/A	N/A	N/A	N/A	%	%	N/A
HCOs	<i>Report per HCO - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate)</i>												
	Mette Haase Moen	Trondheim	Norge	Eirik Jarls gt. 3B No - 7030 Trondheim			0	N/A	N/A	3 000 NOK	0	3 000 NOK	
	HFU-Dagene	Oslo	Norge	Trondheimsveien 2B 0560 Oslo Norge			22 500 NOK	N/A	N/A	0	0	22 500 NOK	
	<i>OTHER, not included above - where information cannot be disclosed per HCO for legal reasons.</i>												
	Aggregate amount attributable to transfers of value to such Recipients - article 10						N/A	N/A	N/A	N/A			
	Number of Recipients						N/A	N/A	N/A	N/A			
% of total number of recipients of individual HCOs - article 10						N/A	N/A	N/A	N/A			N/A	
	Not: N/A = Not Applicable												
R & D	<i>AGGREGATE DISCLOSURE</i>												

Transfers of value re Research & Development (as defined) (article 12 and article 1)